Programme

12:30 – 14:30 ESPT Executive Board meeting – Closed Meeting

15:00 – 15:45 Meeting with ESPT National Representatives – Closed Meeting

16:00 – 17:00 ESPT General Assembly

13:00 – 18:00 Pre – Registration

18:00 – 19:30 OPENING RECEPTION at the congress venue DGI-Byen

• 07.30 Registrations open

 

• 08:45 Opening and Welcome – Lona Louring Christrup

Welcome – Danish Ministry of Health

Welcome on behalf of ESPT – Ann Daly

 

• SESSION: PGx CLINICAL IMPLEMENTATION

Chairs: Lona Christrup & Ann Daly

09:00 A historic overview of pharmacogenetics: Kim Brosen’s perspective – Kim Brøsen

09:30 Implementing pharmacogenomic panel testing in Europe: experiences from the U-PGx PREPARE study – Jesse Swen

09:55 Pharmacogenomics beyond single common genetic variants: the way forward – Magnus Ingelman-Sundberg

 

10:20 – 10:50 COFFEE BREAK

 

• SESSION: PSYCHIATRY

Chairs: Sanja Stankovic & Michael Asger Andersen

10:50 PGx-guided precision dosing of antidepressants – all settled? – Espen Molden

11:15 Applying PGx in Psychiatry: Taking things personally – Daniel Mueller

11.40 Real World Pharmacogenetic experience from a Canadian perspective – Ruslan Dorfman

12:05 Global Diversity Array with enhanced PGx as a method for panel PGx testing: results of a validation study with samples from the PREPARE study – Sylvia Klomp

12:30 Cost-effectiveness of pharmacogenomic-guided treatment: results from a microsimulation model for major depression – Shahzad Ghanbarian

 

12:45 – 13:45 LUNCH / POSTER VIEWING /BOOTH VISITS

 

• SESSION: ONCOLOGY

Chairs: Mikko Niemi & Niels Westergaard

13:45 DPYD pharmacogenetics: the long and winding road to precision dosing of fluoropyrimidines – Erika Cecchin

14:10 Addressing phenoconversion with the Geneva phenotyping cocktail: clinical experience – Caroline Samer

14:35 Drug transporters and novel biomarkers in chemotherapy-induced peripheral neuropathy – Tore Bjerregaard Stage

15:00 Clinical opportunities for germline pharmacogenetics and management of drug-drug interactions in patients with advanced solid cancers – Vicky Pratt

15.25 Germline variants are associated with clinical outcomes and pharmacokinetics in patients with ALK+ NSCLC treated with alectinib – Niels Heersche

 

15:40 – 16:10 TEA BREAK 

 

• SESSION: ctDNA

Chairs: Ron van Schaik & Vita Dolzan

16:10 Liquid Biopsy: From Discovery to Clinical Implementation – Klaus Pantel (KEYNOTE LECTURE)

16:40 Circulating Tumor DNA for Minimal Residual Disease Detection and Risk-Stratified Recurrence Surveillance – Claus Lindbjerg Andersen

17:05 The power of circulating tumor cells in immuno-oncology- Catherine Alix Panabieres

 

• 17:30 CLOSURE

 

• 20:00 CONGRESS DINNER

• SESSION: PGx CHALLENGES

Chairs: Ron van Schaik & Kim Dahlhoff

08:45 Pharmacogenomics of Adverse Drug Reactions – Sir Munir Pirmohamed KEYNOTE LECTURE

09:15 The future of PGx testing; lessons from the 100,000 Genomes project – Matt Brown KEYNOTE LECTURE

09:40 Pharmacogenomics with Rural and Indigenous Communities – Erica Woodahl

 

10:05 – 10:35 COFFEE BREAK 

 

• SESSION: CARDIOLOGY

Chairs: Adrian Llerena & Vangelis Manolopoulos

10:35 Impact of Implementing CYP2C19 Genotype Guided Antiplatelet Treatment in Clinical practice – Wout van den Broek

11:00 Statin pharmacogenetics – clinical relevance and implementation – Mikko Niemi

11:25 Pharmaco(epi)genomics of oral anticoagulation therapy with DOACs – Vangelis Manolopoulos

11:50 Pharmacogenetics in clinical practice, experience and expectations of pharmacogenetic tests – Marieke Coenen

12:15 Exploring the Genetic Basis of Dyspnea in Individuals Treated with Ticagrelor – Marc-Olivier Pilon

 

12:30 – 13:30 LUNCH / POSTER VIEWING /BOOTH VISITS         

 

• SESSION: PERSONALISING DRUG TREATMENT

Chairs: Vita Dolzan & Morton Balzer

13:30 Cocktail approach of probe drugs applying GWAS: Further variants of relevance? – Ingolf Cascorbi

13:55 Clinical scenarios where point of care pharmacogenetic testing improves outcome – William (Bill) Newman

14:20 OPRA (Oncology Precision Project Aarhus); Pharmacogenomically guided treatment for cancer patients – Britt Elmedal Laursen

14:45 Identification of DPYD copy number variation in Finnish population using high-throughput next generation sequencing – Sofia Khan

 

15:00- 15:30 COFFEE BREAK 

 

• SESSION: FOCUS ON THE FUTURE

Chairs: Csilla Sipeky & Jon Thor Traerup Andersen

15:30 Progress at the Danish National Genome Center – Peter Johansen

15:55 Using NGS for PGx – Robert Akkers

16:20 Clinical Pharmacogenetics Implementation in Spanish Health Service (MedeA, IMPaCTm BiofRAM) – Adrian Llerena

 

• 16:45 POSTER PRIZE   

 

• 17:00 CLOSURE

Discussion Forum: How to move forward with implementing PGx?

• 9.30 – 10.00 WELCOME COFFEE

 

• 10:00 – 10:45 PANEL SESSION 1: IMPLEMENTATION

SHORT INTRO: Reflection on implementation of PGx in UK

– Professor Sir Munir Pirmohamed, MD/PhD

– Erika Cecchin – Italy (Oncology)

– Britt Elmedah Laursen – Denmark (Oncology)

– Adrian Llerena – Spain (PGx-implementation)

– Daniel Mueller – Canada (Psychiatry)

– William (Bill) Newman – England (Clinical Genetics)

– Mikko Niemi – Finland (general PGx services)

– Jesse Swen – The Netherlands (PGx-services)

 

• 10:45 – 11:15 PANEL SESSION 2: INDUSTRY VIEW 

SHORT INTRO: PGx in the near future: a laboratory perspective

– Daniel Langhoff – Director Eurofins Genomics, Denmark

– Ruslan Dorfman – Pillcheck Canada 

– Tiffany Morris – Illumina

– Vicky Pratt – AGENA Bioscience 

– Dominique Dewolf – Thermo Fisher Scientific 

 

• 11:15 – 11:45 PANEL SESSION 3: PGx RESEARCH

SHORT INTRO: Which (additional) research is needed?

– Magnus Ingelman-Sundberg – Karolinska Instituten, Sweden

– Matt Brown – Biobank – Genomics England

– Kim Brosen, Clinical Pharmacology – Denmark

– Ingolf Cascorbi – Clinical Pharmacology – Germany

 

• 11.45 CLOSURE + Announcement 2025 ESPT venue – Ann Daly